Jazz Pharmaceuticals (JAZZ) Total Debt (2010 - 2026)

Jazz Pharmaceuticals' Total Debt history runs 17 years deep, the most recent figure standing at $5.4 billion for Q1 2026.

• In Q1 2026, Total Debt changed 0.24% year-over-year to $5.4 billion; the TTM figure through Mar 2026 stood at $5.4 billion (changed 0.24% YoY), while the FY2025 annual figure was $5.4 billion, down 12.28% from the prior year.
• Total Debt was $5.4 billion for Q1 2026 at Jazz Pharmaceuticals, roughly flat from $5.4 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $6.1 billion in Q3 2024 to a low of $5.4 billion in Q1 2026.
• Historically, Total Debt has averaged $5.7 billion across 5 years, with a median of $5.7 billion in 2023.
• The sharpest annual moves came in 2022 and 2025: Total Debt jumped 186.63% in 2022, then retreated 12.28% in 2025.
• A 5-year view of Total Debt shows it stood at $5.7 billion in 2022, then declined by 0.2% to $5.7 billion in 2023, then advanced by 6.93% to $6.1 billion in 2024, then decreased by 12.28% to $5.4 billion in 2025, then slipped by 0.07% to $5.4 billion in 2026.
• The last three Total Debt figures came in at $5.4 billion (Q1 2026), $5.4 billion (Q4 2025), and $5.4 billion (Q3 2025), per Business Quant data.